Curis Lifesciences IPO is a book build issue of ₹27.52 crores. The issue is entirely a fresh issue of 0.22 crore shares of ₹27.52 crore.
Curis Lifesciences IPO opens for subscription on Nov 7, 2025 and closes on Nov 11, 2025. The allotment for the Curis Lifesciences IPO is expected to be finalized on Nov 12, 2025. Curis Lifesciences IPO will list on NSE SME with a tentative listing date fixed as Nov 14, 2025.
Curis Lifesciences IPO price band is set at ₹120.00 to ₹128.00 per share . The lot size for an application is 1,000. The minimum amount of investment required by an individual investor (retail) is ₹2,56,000.00 (2,000 shares) (based on upper price). The minimum lot size investment for HNI is 3 lots (3,000 shares), amounting to ₹3,84,000.
Finaax Capital Advisors Private Limited is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is RS Wealth Management Private Limited.
Refer to Curis Lifesciences IPO RHP for detailed Information.
Submit your IPO application online through your preferred broker — fast, secure, and reliable.
| IPO Date | November 7, 2025 to November 11, 2025 |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Issue Price Band | ₹120 to ₹128 per share |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 21,50,000 shares (aggregating up to ₹27.52 Cr) |
| Reserved for Market Maker | 1,08,000 shares RS Wealth Management Private Limited (aggregating up to ₹1.38 Cr) |
| Net Offered to Public | 20,42,000 shares (aggregating up to ₹26.14 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 59,34,434 shares |
| Share Holding Post Issue | 80,84,434 shares |
Curis Lifesciences IPO offers total 21,50,000 shares. Out of which 10,18,000 (47.35%) allocated to QIB, 4,08,000 (18.98%) allocated to QIB (Ex- Anchor), 3,08,000 (14.33%) allocated to NII 7,16,000 (33.30%) allocated to RII and 6,10,000 (28.37%) allocated to Anchor investors.
| Investor Category | Shares Offered |
|---|---|
| Market Maker Shares Offered | 1,08,000 (5.02%) |
| QIB Shares Offered | 10,18,000 (47.35%) |
| − Anchor Investor Shares Offered | 6,10,000 (28.37%) |
| − QIB (Ex. Anchor) Shares Offered | 4,08,000 (18.98%) |
| NII (HNI) Shares Offered | 3,08,000 (14.33%) |
| Retail Shares Offered | 7,16,000 (33.30%) |
| Total Shares Offered | 21,50,000 (100.00%) |
Curis Lifesciences IPO raises ₹7.81 crore from anchor investors. Curis Lifesciences IPO Anchor bid date is November 6, 2025.
| Bid Date | November 6, 2025 |
| Shares Offered | 6,10,000 |
| Anchor Portion Size (In Cr.) | 7.81 |
| Anchor lock-in period end date for 50% shares (30 Days) | December 12, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | February 10, 2026 |
Curis Lifesciences IPO opens on November 7, 2025, and closes on November 11, 2025.
| IPO Open Date | Fri, Nov 7, 2025 |
| IPO Close Date | Tue, Nov 11, 2025 |
| Tentative Allotment | Wed, Nov 12, 2025 |
| Initiation of Refunds | Thu, Nov 13, 2025 |
| Credit of Shares to Demat | Thu, Nov 13, 2025 |
| Tentative Listing Date | Fri, Nov 14, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Tue, Nov 11, 2025 |
Investors can bid for a minimum of 2,000 shares and in multiples of 1,000 shares thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,56,000 |
| Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,56,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,84,000 |
| S-HNI (Max) | 7 | 7,000 | ₹8,96,000 |
| B-HNI (Min) | 8 | 8,000 | ₹10,24,000 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.
The company manufactures pharmaceutical products globally and domestically on a loan license or contract basis, as well as for its own brand marketing.
The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya.
Products:
The company operates a state-of-the-art manufacturing facility in Sanand, Gujarat, adhering to stringent quality control measures to ensure product safety and efficacy.
As of July 31, 2025, the company has 95 permanent employees.
Competitive Strengths:
Curis Lifesciences Ltd.'s revenue increased by 38% and profit after tax (PAT) rose by 25% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 31 Jul 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 56.29 | 42.53 | 33.88 | 29.75 |
| Total Income | 19.51 | 49.65 | 35.87 | 36.42 |
| Profit After Tax | 2.87 | 6.11 | 4.87 | 1.88 |
| EBITDA | 4.24 | 9.54 | 8.39 | 3.28 |
| NET Worth | 19.10 | 16.23 | 5.87 | 1.01 |
| Reserves and Surplus | 13.16 | 10.29 | 5.37 | 0.51 |
| Total Borrowing | 15.32 | 15.62 | 17.09 | 16.19 |
| Amount in ₹ Crore | ||||
KPI as of Mon, Mar 31, 2025.
| KPI | Values |
|---|---|
| ROE | 55.25% |
| ROCE | 27.83% |
| Debt/Equity | 0.96 |
| RoNW | 37.62% |
| PAT Margin | 12.43% |
| EBITDA Margin | 19.41% |
| Price to Book Value | 12.64 |
| Market Capitalization | 103.48 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 10.29 | 10.66 |
| P/E (x) | 12.44 | 12.01 |
The Company Curis Lifesciences IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|---|
| 1 | Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities | 2.44 |
| 2 | Capital Expenditure towards Construction of a Storage Facility | 3.62 |
| 3 | Pre-payment/Repayment of outstanding Secured Loans | 1.86 |
| 4 | Product Registrations in other countries | 2.69 |
| 5 | Funding our Working Capital Requirements | 11.25 |
| 6 | General Corporate Purposes |
[Dilip Davda] CLL is engaged in manufacturing pharma products on contract/loan license basis. It posted growth in its top and bottom lines for the reported periods. Boosted profits from FY24 onwards raise eyebrows and concern over its sustainability as it is operating in a highly competitive and fragmented segment. Based on its recent financial data, the issue appears fully priced. Small equity base post-IPO indicates longer gestation for migration. Only well-informed/cash surplus investors may park moderate funds for medium term. Read detail review...
Curis Lifesciences Ltd.
PF-23, GIDC Sanand - II,
Industrial Estate,
Sanand
Ahmedabad, Gujarat, 382110
Phone: +91 99045 22543
Email: cs@curisls.com
Website: https://curisls.com/
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: curislifesciences.smeipo@in.mpms.mufg.com
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Curis Lifesciences IPO is a SME IPO of 21,50,000 equity shares of the face value of ₹10 aggregating up to ₹27.52 Crores. The issue is priced at . The minimum order quantity is 1000.
The IPO opens on November 7, 2025, and closes on November 11, 2025.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Curis Lifesciences IPO using UPI as a payment gateway. Zerodha customers can apply in Curis Lifesciences IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Curis Lifesciences IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Curis Lifesciences IPO opens on November 7, 2025 and closes on November 11, 2025.
Curis Lifesciences IPO lot size is 1000, and the minimum amount required for application is ₹2,56,000, with 2 lots being the minimum application size.
You can apply in Curis Lifesciences IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Curis Lifesciences IPO will be done on Wednesday, November 12, 2025, and the allotted shares will be credited to your demat account by Thursday, November 13, 2025. Check the Curis Lifesciences IPO allotment status.
The Curis Lifesciences IPO listing date is not yet announced. The tentative date of Curis Lifesciences IPO listing is Friday, November 14, 2025.
Useful Articles
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
RHP
